300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

EQS-News: BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco

EQS-News: BioLizard nv / Key word(s): Personnel/Conference
BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco

09.01.2025 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco
 
  • Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences
  • Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech Showcase during JP Morgan Week (Jan 13-15, 2025) in San Francisco
  • Discover Bio|Verse® Navigator, BioLizard’s newly launched AI-native application that transforms complex biomedical data into actionable insights and accelerates data-driven R&D in life sciences
Ghent (Belgium), January 9, 2025 – BioLizard, a leading provider of bioinformatics, data analytics and data management services and consulting company heading digital transformation in the life sciences industry, today announced the appointment of Arjan van Manen as Commercial Director. With his experience in strategic commercial development and in driving innovative solutions for biotech and pharma companies, Arjan will be instrumental in leading the company into the next phase of growth.

Liesbeth Ceelen, PhD, MBA, CEO of BioLizard, commented: “We are thrilled to welcome Arjan to our team of Lizards. His track record in sales and marketing management, strategic planning, and business growth, paired with his deep understanding of both the European and global life sciences markets, make Arjan an ideal fit for BioLizard. He will be instrumental in accelerating our mission to advance digital transformation across the life sciences sector.”

Arjan van Manen added: “I am delighted to join BioLizard’s team of experts. The company’s unique and impressive blend of cutting-edge bioinformatics, AI-driven data engineering, and scientific expertise perfectly positions it to address the challenges modern biotech, pharma, and healthcare organizations face every day. I look forward to working closely with the team and our partners to help shape the future of data-driven innovation. The team has translated its data science competence in an impressive AI-native platform that provides new opportunities for customer engagement. This suite of analytical tools is designed to lead to actionable scientific insights for drug and biomarker discovery in early clinical research and plant and animal research.”

Arjan brings over 20 years of experience in the life sciences industry, with a strong focus on commercial leadership and strategic business development. As Commercial Director at BioLizard, his focus will be on leading the team in the growth strategy of geographical expansion and introduction of novel solutions and tools that enable actionable biology insights. Arjan most recently served as Chief Strategy Officer at SkylineDx, where he shaped global commercial strategies in oncology diagnostics. His earlier roles at SkylineDx included EVP Business and Commercial Development and Regional Business Manager, further demonstrating his expertise in international market expansion. During his time at Bristol-Myers Squibb, Arjan led Immuno-Oncology and Hematology sales across the Benelux region and oversaw the successful launches of new therapies. With additional leadership positions at Takeda Pharmaceuticals and LifeCell Corporation, he has consistently driven growth and achieved impactful business results.

BioLizard recently launched Bio|Verse Navigator, an innovative application that empowers scientists to transform complex biomedical data into actionable insights. This application significantly accelerates data exploration and interpretation workflows, reducing time-to-insight for researchers and fostering seamless collaboration across internal and external data repositories. This is achieved by merging advanced bioinformatics expertise with powerful   visual analytics, reducing the complexity of handling multiple data parameters.

Bio|Verse is the technical translation of BioLizard’s strengths in biology, AI, ML, and data engineering and serves as a solution for multi-omics and clinical research activities, enabling scientists to shorten discovery times for biomarkers, understand disease mechanisms, and accelerate drug discovery.
 
JP Morgan Week: Meet Arjan van Manen and our CEO Liesbeth Ceelen at Biotech Showcase in San Francisco, January 13-15, 2025, to learn more about BioLizard’s innovative solutions. Schedule a meeting through the or get in touch with us directly.


About BioLizard
BioLizard is a leading multi-national bioinformatics, data engineering and biopharma consulting services company, heading digital transformation in the life sciences industry. Headquartered in Ghent, Belgium, BioLizard is the trusted go-to partner for data strategy and execution with companies across the range from drug discovery to clinical research and diagnostics as well as animal health and food & agriculture. BioLizard accommodates a uniquely qualified team of 50+ experts, “The Lizards”, who bring together their overarching expertise, living and breathing the company’s ethos: Think Data, Speak Biology. Their joint backgrounds in biology and computer science enable them to apply specialist understanding to each client’s data environment, provide insights and solutions that are aligned with the client’s goals and maximize R&D ROI. With Bio|Verse, BioLizard takes the next step in providing bespoke software solutions by tailoring its established programs towards specific client needs. For further information, please visit or BioLizard’s .
 
Contact
BioLizard nv
Liesbeth Ceelen, PhD, MBA
Phone: 2
E-mail:
Media Inquiries
MC Services AG
Eva Bauer
Phone: +49 (0)89 2102280
E-mail:


09.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: BioLizard nv
Ottergemsesteenweg Zuid 808 bus B511
9000 Gent
Belgium
E-mail:
Internet:
EQS News ID: 2064723

 
End of News EQS News Service

2064723  09.01.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2064723&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
09/01/2025

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

EQS-News: vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage

Emittent / Herausgeber: ibw – Informationszentrale der Bayerischen Wirtschaft e. V. / Schlagwort(e): Sonstiges/Sonstiges vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage 10.04.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. vbw zum Koalitionsvertrag: Gute Grundlage Brossardt: „Koalitionsvertrag schafft Planungssicherheit und setzt Wachstumsimpulse“  Bertram Brossardt, Hauptgeschäftsführer der vbw – Vereinigung der Bayerischen Wirtschaft e. V.: (München, 09.04.2025). Wir freuen uns, dass jetzt der Weg frei ist f...

 PRESS RELEASE

Aquis Stock Exchange - suspension of trading

Aquis Stock Exchange Aquis Stock Exchange - suspension of trading 10-Apr-2025 / 07:00 GMT/BST The issuer is solely responsible for the content of this announcement. The following securities are suspended from trading on the Aquis Growth Market from 08.00, 10 April 2025, at the request of the company: Richmond Hill Resources Plc Ordinary Shares Symbol: SHNJ ISIN: GB00BNTBWF32 The Regulation Department Aquis Stock Exchange Floor 2, 63 Queen Victoria Street, EC4N 4UA Tel: 0203 597 6361 Email:  Website:  Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The i...

 PRESS RELEASE

EQS-News: CO2Coin one of the most successful crypto investments of the...

Issuer: Clima4Future Ltd. / Key word(s): Cryptocurrency / Blockchain/Market Launch CO2Coin one of the most successful crypto investments of the coming decades. 10.04.2025 / 04:55 CET/CEST The issuer is solely responsible for the content of this announcement.     CO2Coin is going through a phase of phenomenal growth. A year ago the price was just €1, today it is around 270 USDT - an increase in value that illustrates the enormous potential of this unique project. This development reflects the crypto community's growing interest in sustainable investments. Clima4Future Lt...

 PRESS RELEASE

EQS-News: CO2Coin eine der erfolgreichsten Krypto-Investitionen der ko...

Emittent / Herausgeber: Clima4Future Ltd. / Schlagwort(e): Kryptowährung / Blockchain/Markteinführung CO2Coin eine der erfolgreichsten Krypto-Investitionen der kommenden Jahrzehnte. 10.04.2025 / 04:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Der CO2Coin hat einen beeindruckenden Kursanstieg erlebt. Vor einem Jahr lag der Kurs noch bei 1 €, heute liegt er bei rund 270 USDT - eine Wertsteigerung, die das enorme Potenzial dieses einzigartigen Projekts verdeutlicht. Diese Entwicklung spiegelt das wachsende Interesse der Krypto-Com...

 PRESS RELEASE

EQS-News: Zimbabwe Government Delivers on Commitment: Compensation of ...

EQS-News: Zimbabwe Ministry of Finance, Economic Development and Investment Promotion / Key word(s): Miscellaneous Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences 09.04.2025 / 20:20 CET/CEST The issuer is solely responsible for the content of this announcement. In line with the GCD agreement, the FFOs receive 1 per cent of their claim in cash, with the balance being paid through US$ denominated Treasury bonds with a 2 per cent coupon and maturities of 2 to 10 years HARARE, Zimbabwe, April 9, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch